Page 2 - Zydus Lifesciences

Zydus Lifesciences marks China entry with approval for antidepressant drug

Indian drug cos Chinese pipelines start getting regulator nod; Glenmark got nod for nasal spray this week

Zydus Life Q2: Solid beat on bottom line, analysts mixed on growth outlook

Zydus Life Q2 results review: Foreign brokerage Nomura said Zydus Life delivered results above estimates, led by a stronger-than-expected performance in India.

Zydus PAT up 38% on strong India, US growth; board okays ₹5K cr fundraise

Zydus Lifesciences reported a 17% YoY rise in revenue to Rs 6,123 crore and a 38% jump in profit to Rs 1,258.6 crore in Q2 FY26, driven by India and US formulations performance

Zydus gets USFDA's orphan drug designation for beta-thalassemia product

Zydus Lifesciences on Thursday said the US health regulator has granted Orphan Drug Designation (ODD) to Desidustat, a novel product for the treatment of beta-thalassemia. The US Food and Drug Administration (USFDA) grants orphan status to support development of medicines for the treatment of rare diseases that affect fewer than 2 lakh people in the US. "This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop Desidustat to address beta-thalassemia," Zydus Lifesciences MD Sharvil Patel said in a regulatory filing. Beta thalassaemia patients have low levels of haemoglobin, which results in a lack of oxygen in many parts of the body, leading to weakness, fatigue and more serious complications. Treatment for people with beta thalassaemia often requires lifelong regimens of chronic blood transfusions for survival and treatment for iron overload due to the transfusions. Desidustat is a hypoxia inducible factor (HIF)-prolyl hydroxylase inhibitor (PHI) an

Stocks to Watch today, Nov 4: Bharti Airtel, Titan, Hero MotoCorp, Cipla

Stocks to Watch today, November 4, 2025: From Bharti Airtel, Hero MotoCorp, Titan Company, and Power Grid, here is a list of stocks that will be in focus today

Stocks to Watch today, Oct 7: LTIMindtree, Bank of India, HCL Tech, OIL

Stocks to Watch today, October 7, 2025: From Bank of India, HCL Tech to Eternal, here is a list of stocks that will be in focus

IPA appoints Zydus Lifesciences MD Sharvil Patel as new President

Sharvil Patel takes over as President of IPA from Samir Mehta, with Glenn Saldanha appointed Vice President, as the industry navigates reforms and global challenges

Zydus Lifesciences growth aided by acquisitions, but execution risks loom

Zydus Lifesciences trades near 52-week highs on strong growth and acquisitions but analysts caution that rapid expansion and diversification may pose execution challenges

ICMR licences multi-stage malaria vaccine 'AdFalciVax' to five companies

The selection of companies was made through an Expression of Interest (EoI) process launched by ICMR in July

Zydus Lifesciences' Q1 dose lifts vitals, but outlook stays fragile

April-June Qtr beat offsets some caution, yet US headwinds cap upside

Zydus Lifesciences Q1 PAT up 5.9% on strong India, int'l formulations biz

The growth was driven by strong performances in the company's domestic and international formulations segments, even as its consumer wellness and US businesses saw muted growth

Zydus Lifesciences Q1 results: Profit up 3% at ₹1466.8 cr, revenue rises 6%

Revenue from operations climbed 5.9 per cent Y-o-Y to ₹6,573.7 crore in Q1 FY26 from ₹6,207.5 crore a year earlier on the back of new drug launches in the US

Zydus gets USFDA approval for a high blood pressure to treat angina

Zydus Lifesciences on Monday said it has received approval from the US health regulator to market a drug used to treat angina and high blood pressure. The company has received final approval from the US Food and Drug Administration (USFDA) for Diltiazem Hydrochloride tablets in strengths of 30 mg, 60 mg, 90 mg, and 120 mg, the drug maker said in a statement. Diltiazem Hydrochloride Tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm. It belongs to a class of drugs called calcium-channel blockers. Diltiazem works by relaxing blood vessels, which reduces the workload on the heart and increases blood and oxygen supply to the heart muscle. The company said Diltiazem Hydrochloride Tablets will be produced at Zydus Lifesciences' Baddi plant in Himachal Pradesh. As per IQVIA MAT June 2025 data, Diltiazem Hydrochloride Tablets had annual sales of USD 13.9 million in the US.

Zydus Lifesciences up 2% after USFDA nods Diltiazem Hydrochloride tablets

Zydus Lifesciences share price rose 2 per cent, logging an intra-day high at ₹955 per share on BSE after USFDA gave its approval for Diltiazem Hydrochloride Tablets.

Dr Reddy's Labs, Lupin: Nifty Pharma slips 2% amid Trump tariff jitters

Nifty Pharma index declined 1.5 per cent in trade after US President Donald Trump warned to impose a 25 per cent tariff on Indian goods starting August 1

Zydus Lifesciences gets tentative USFDA nod for generic blood cancer drug

Zydus Lifesciences Ltd on Thursday said it has received tentative approval from the US health regulatory agency for its generic version of cancer treatment drug Ibrutinib tablets. The tentative approval granted by the US Food and Drug Administration (USFDA) is for Ibrutinib tablets of strengths 140 mg, 280 mg, and 420 mg, Zydus Lifesciences said in a statement. The Ibrutinib tablets will be produced at Zydus Lifesciences Ltd SEZ, Ahmedabad, it added. The company said Ibrutinib is indicated for the treatment of adult patients with different types of blood cancers, Chronic lymphocytic leukaemia (CLL)/Small lymphocytic lymphoma (SLL), and Waldenstrom's macroglobulinemia (WM). Citing IQVIA MAT May 2025, Zydus said Ibrutinib tablets had annual sales of USD 2148.9 million in the US.

Zydus Lifesciences gets USFDA nod for its painkiller Celecoxib capsules

The company said that the medicine is used to treat pain or inflammation caused by many conditions such as arthritis, ankylosing spondylitis, and menstrual pain

Stocks to Watch today, July 14: VIP Industries, Adani Green, NCC, DMart

Stocks to Watch today, July 14, 2025: Glenmark Pharma, Avenue Supermarts, RVNL and NCC are some of the top stocks to watch today

Stocks to Watch today, June 19: Jio Financial, Inventurus, Hero MotoCorp

Stocks to Watch today, June 19: Jio Financial, Inventurus Knowledge, Hero MotoCorp, Zydus Lifesciences, Vodafone Idea are among stocks that may buzz in trade

Breakout stocks: Nifty Pharma, Biocon, Cipla break over 200-DMA; what next?

The Nifty Pharma index and select shares such as Biocon, Cipla, Zydus Life and Gland Pharma were trading above the respective 200-DMAs after more than 2 months; show technical charts.